improvements" in pain relief and functional improvement, respectively, with TA-ER (43%, 43%) compared to IACS (13%, 13%) and IAHA (19%, 13%). More patients reported a longer duration of pain relief and functional improvement (months), respectively, with TA-ER (51%, 44%) versus IACS (28%, 28%) and IAHA (19%, 25%). Conclusions: Knee OA has a tremendous impact on quality of life, and patients have significant unmet treatment needs. Patients and physicians identified similar attributes as very important in making knee OA treatment decisions. TA-ER is a useful addition to the physicians' armamentarium with patients reporting a higher magnitude and duration of knee OA symptom relief relative to other IA injections.
identified from the MEPS data based on the Andersen's Behavioral Model of Health Services Use. Generalized linear models were performed to determine the presence of mediation using the Barron and Kenny approach. Results: A total of 119 eligible individuals, representing 1,360,803 individuals were included in this study. The sample included 76% females, 75% Caucasians, 38% over the age of 65 years, and 84% reporting at least one comorbidity, with a mean family income of $61,323. The mediation analysis showed that after controlling for covariates, race was significantly associated with direct medical costs (Estimate = 0.96; SE = 0.26; p < 0.05), and but not medication adherence (Estimate = 0.033; SE: 12; p > 0.05). Medication adherence was significantly related to medical costs (Estimate = 0.40; SE: 0.14; p < 0.05). ConClusions: Adherence to DMARDs was not found to be a mediator of the relationship between race/ethnicity and healthcare cost. Further analysis needs to be conducted to explore the mediators of racial disparities in overall medical costs among patients with RA.
s201were from all regions of the United States (Northeast, 19.3%; North Central, 15.7%; South, 44.7%; West, 16.1%; Puerto Rico/Virgin Islands, 0.4%); approximately 60% of patients were female and the mean (SD) age was 53.6 (12.0) years. Overall, 6.1% of patients were biologic naive, 41.9% received ≥ 1 prior biologic therapy, and 52.0% had missing information about prior biologic use. Among patients with prior biologic use, 38.6% had 1 reported biologic efficacy failure, 33.8% had 2 efficacy failures, and 27.7% had ≥ 3 efficacy failures; the most commonly reported biologic efficacy failures were adalimumab (67.4%) and etanercept (59.1%). For both initial and maintenance dosing, approximately half of patients were prescribed secukinumab 300 mg (51.1% and 51.6%, respectively). ConClusions: In this analysis of SRFs filled by patients with PsA and their health care providers, approximately half of patients were prescribed secukinumab 300 mg for both initial and maintenance dosing. These results provide early insights into the prescribing patterns of secukinumab for PsA in a US real-world setting. Future research is needed to better understand how clinical characteristics and treatment history may affect secukinumab usage in US patients with PsA.
identified from the MEPS data based on the Andersen's Behavioral Model of Health Services Use. Generalized linear models were performed to determine the presence of mediation using the Barron and Kenny approach. Results: A total of 119 eligible individuals, representing 1,360,803 individuals were included in this study. The sample included 76% females, 75% Caucasians, 38% over the age of 65 years, and 84% reporting at least one comorbidity, with a mean family income of $61,323. The mediation analysis showed that after controlling for covariates, race was significantly associated with direct medical costs (Estimate = 0.96; SE = 0.26; p < 0.05), and but not medication adherence (Estimate = 0.033; SE: 12; p > 0.05). Medication adherence was significantly related to medical costs (Estimate = 0.40; SE: 0.14; p < 0.05). ConClusions: Adherence to DMARDs was not found to be a mediator of the relationship between race/ethnicity and healthcare cost. Further analysis needs to be conducted to explore the mediators of racial disparities in overall medical costs among patients with RA.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.